IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) subsidiary Imaging Biometrics has received approval for an Expanded Access Program (EAP) for oral gallium maltolate (GaM) from the US Food and Drug Administration.
As a result, the treatment, which has the potential to slow brain tumour growth is now available to patients in the US with relapsed or refractory histologic or molecular glioblastoma
This EAP will run in parallel with the current phase I clinical trial being conducted at the Medical College of Wisconsin, IQ_AI said.
As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US can choose to participate in the EAP.
Several patients have registered to participate in the EAP, and a total of 40 patients can enrol in this initial phase.
"Providing eligible patients access to GaM as a potential treatment ahead of regulatory approval underscores our commitment to helping address a clear unmet patient need," said Trevor Brown, IQ-AI’s chief executive.